Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Elinzanetant→

Elinzanetant Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
929046-33-3
Molecular formula
C33H35F7N4O3
Molecular weight
668.6 g/mol
Drug class
Neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonistnon-hormonal therapy for menopausal vasomotor symptoms
Mechanism of action
Antagonises NK1 and NK3 receptors in thermoregulatory pathways, modulating neurokinin-mediated signalling involved in menopausal vasomotor symptoms. It is not an oestrogen replacement therapy.
Indications / reported uses
  • Treatment of moderate-to-severe vasomotor symptoms (hot flushes and night sweats) due to menopause under the US FDA LYNKUET indication approved in 2025

Sources: US FDA approval letter — LYNKUET (elinzanetant) · US DailyMed — LYNKUET · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist; non-hormonal therapy for menopausal vasomotor symptoms

Mechanism of action

Antagonises NK1 and NK3 receptors in thermoregulatory pathways, modulating neurokinin-mediated signalling involved in menopausal vasomotor symptoms. It is not an oestrogen replacement therapy.

General use cases

  • Treatment of moderate-to-severe vasomotor symptoms (hot flushes and night sweats) due to menopause under the US FDA LYNKUET indication approved in 2025

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Elinzanetant Environmental Risk Assessment (ERA) (the Elinzanetant ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.